Ethinyl Estradiol and Norelgestromin (Transdermal)

Ethinyl estradiol and norelgestromin, applied topically via a patch, is a powerful form of hormonal contraceptive.

Overview

Ethinyl estradiol and norelgestromin are the two active ingredients of the contraceptive patch, often called simply œthe patch. It works by preventing ovulation, which means it not only is effective as a contraceptive, but can also bring relief to women afflicted by especially painful periods.

When used perfectly (changed weekly, on the same day), it has a failure rate of 0.3%. However, due to misuse, the ethinyl estradiol and norelgestromin patch has a real fail rate of around 9%.

After a competitor stopped selling the ethinyl estradiol and norelgestromin patch in 2016, the patch is only available under the brand name Xulane, manufactured by the company Janssen-Ortho.

Conditions Treated

  • Ovulation

Type Of Medicine

  • Contraceptive
  • Hormonal birth control

Side Effects

Overdose can occur in users of the ethinyl estradiol and norelgestromin patch. Symptoms of overdose include vaginal bleeding and vomiting. Patients who experience any symptoms of an overdose on ethinyl estradiol and norelgestromin should contact their doctor immediately.

Application of the ethinyl estradiol and norelgestromin patch can cause a wide variety of side effects, as well as the primary anti ovulation effect. Some of these side effects may be serious and warrant medical attention. Other side effects may only be as serious as the discomfort they cause the patient. Patients should remember that the ethinyl estradiol and norelgestromin patch contains powerful hormones and has the power to disrupt bodily processes. Patients should be sure that they are prepared to face the side effects if they decide to use the ethinyl estradiol and norelgestromin patch.

Patients who begin to experience any of the following symptoms should consult with their doctor immediately. Medical attention may be necessary.

  • Body aches
  • Body pain
  • Fever
  • Sneezing
  • Coughing
  • Chills
  • Headache
  • Sore throat
  • Sudden loss of voice
  • Unusual or inexplicable tiredness
  • Unusual or inexplicable weakness
  • Difficult or labored breathing
  • Congested'stuffy' nose
  • Runny nose
  • Congested ears

The following side effects have been reported by patients using the ethinyl estradiol and norelgestromin patch, but the exact incidence of them is not known. Nevertheless, patients should be prepared to face these side effects if they choose to use the ethinyl estradiol and norelgestromin patch. Patients who begin to experience any of the following side effects should contact their doctor immediately. Medical attention may be necessary.

  • Anxiety
  • Tenderness, swelling, or pain in the legs or feet
  • Changes or discolorations in skin color
  • Pounding in the ears
  • Chest pain
  • Discomfort in the chest
  • Rash
  • Sudden confusion
  • Seizures
  • Dark or discolored urine
  • Elevated heart rate
  • Lowered heart rate
  • Diarrhea
  • Dizziness
  • Slurred speech
  • Headaches
  • Pain in the eyes
  • Sudden loss of coordination
  • Fainting
  • Sudden and severe weakness or numbness in the leg on one side of the body
  • Sudden and severe weakness or numbness in the arm on one side of the body
  • Inability to speak
  • Sudden and inexplicable shortness of breath
  • Itching
  • Sudden sweating
  • Sudden loss of appetite
  • Sweating
  • Lightened or otherwise discolored stools
  • Tenderness, swelling, or pain in the upper abdomen/stomach
  • Lightheadedness
  • Nausea
  • Temporary blindness
  • Numbness in the hands
  • Halitosis
  • Pain in the stomach or abdomen
  • Changes to vision
  • Vomiting blood
  • Pain in the groin, chest, or legs, especially in the calves
  • Pain or discomfort in the arms, back or neck
  • Yellow discoloration of the skin or eyes

Not all side effects of the ethinyl estradiol and norelgestromin patch are serious or demand medical attention. Some side effects are simply the byproduct of the body adapting to the sudden influx of new medicine. Patients who begin to experience any of the following side effects should consult with their doctor to find out how to mitigate or otherwise lessen their most unpleasant symptoms.

  • Burning or itching sensations on the skin
  • Red discoloration of the skin
  • Pain soreness, or swelling of the breasts
  • Painful discharge from the breasts
  • Swelling or soreness at the site of the ethinyl estradiol and norelgestromin patch

Patients have reported experiencing the following symptoms, but the exact incidence of the following symptoms is unknown. Nevertheless, patients who plan to use the ethinyl estradiol and norelgestromin patch should be prepared to deal with the following side effects.

  • Abdominal or stomach cramps
  • Bloating of the stomach
  • Irregular or absent menstrual periods
  • Bloody vaginal discharge
  • Brown, blotchy spots on exposed skin
  • Changes to the volume of vaginal discharge
  • Changes to the menstrual flow
  • Decreases in the volume of breast milk
  • Feelings of discouragement
  • Dry mouth
  • Feelings of sadness or emptiness
  • Fluctuations in weight
  • Sudden weight gain
  • Sudden weight loss
  • Increased hunger
  • Increased thirst
  • Increased urination
  • Irritability
  • Itching sensations on the vagina or exterior of the genitals
  • Some vaginal bleeding between periods
  • Some vaginal bleeding during or after sexual intercourse
  • Loss of interest
  • Loss of pleasure
  • Pain during sexual intercourse
  • Cessation of menstrual bleeding
  • Generalized swelling
  • Thick, white vaginal discharge, not unlike curds. Minimal to moderate odor
  • Difficulty concentrating
  • Difficulty falling and staying asleep

In general, patients in studies most frequently reported feeling effects on their breasts, along nausea and vomiting. Patients should expect to experience the aforementioned side effects if they decide to use the ethinyl estradiol and norelgestromin patch.

This is not necessarily a comprehensive list of side effects. Patients who begin to experience new or worsening symptoms after beginning to use the ethinyl estradiol and norelgestromin patch should contact their doctor immediately. Patients can report new side effects to the FDA by dialing 1(800) FDA-1088 or on the web by going to www.fda.gov/medwatch.

Dosage

The following instructions are for the purpose of contraception. If a patient has been instructed by their doctor to use the ethinyl estradiol and norelgestromin patch for a reason other than contraception, that patient should follow their doctor's directions.

For the purposes of contraception, patient should apply one new patch to their arm every week for three weeks. On the fourth week, patients should go patch free. During this week, patients will be most likely to experience side effects which affect menstruation.

Patients should change their patch on the same day of the week, every week. By waiting extra day or more, patients run the risk of the contraceptive failing. By changing a day or more early, patients will simply be wasting medicine.

The patch can be placed anywhere on the patients upper arm, abdomen, buttock or back. Patients should ensure they place the patch in place which will not experience rubbing, whether form tight clothing or from other parts of their body.

Patients should never place the patch on their breasts or on cut or irritated skin. Patients should also make sure to never place a patch in the same location the patch they were replacing is on.

Patients should be aware that if they are over 90kg the patch may be less effective. Patients over 90 kg may want to consult with their doctor to discover alternative forms of contraception.

Patients who miss a dose should consult with their doctor to determine the best way to proceed. Patients should be aware that if they miss a dose (meaning forget to change the patch on the day they normally do) the contraceptive may not longer be working.

Patients who wish to move from taking a contraceptive pill or using a contraceptive ring to using the ethinyl estradiol and norelgestromin patch should complete their pill or ring cycle as usual. Then, at the start of a new cycle, begin to use the patch instead of the contraceptive ring or pill. If, within a week, the patient has not gotten their period, then the ethinyl estradiol and norelgestromin patch will be working.

Patients should not cut, alter, or damage the ethinyl estradiol and norelgestromin patch in any way. Patients should be sure to apply the patch completely to clean, dry skin. Patients should not apply the patch over moisturizer, lotion, skin cream, or any other product. Doing so may cause a decrease in the contraceptive effects of the ethinyl estradiol and norelgestromin patch.

In the case of a first trimester abortion or com/health/miscarriage/">miscarriage then patients may begin to use the ethinyl estradiol and norelgestromin patch right away. Additional contraceptives may be necessary.

Patients who experience a second trimester abortion or miscarriage should wait at least four weeks before using an ethinyl estradiol and norelgestromin patch. This is due to an increased risk of thromboembolic disease which the ethinyl estradiol and norelgestromin patch would compound.

Patients may begin to use the ethinyl estradiol and norelgestromin as soon as 4 weeks after childbirth, provided they are not breastfeeding. Additional contraceptives may be necessary.

The dosages and procedures detailed above describe averages and standard practices. Standard practice may not be right for every patient. Patients should rely on their doctor to determine the proper dosage and procedure for them to use the ethinyl estradiol and norelgestromin patch.

Interactions

Smoking cigarettes while using the ethinyl estradiol and norelgestromin patch will put the patient at serious risk of adverse cardiovascular effects. This risk increases with age. At age 35 and beyond, patients who smoke are usually advised against using the ethinyl estradiol and norelgestromin patch. Patients below 35 who smoke and want to use the ethinyl estradiol and norelgestromin patch should consult with their doctor to discover alternative options for contraception.

A wide variety of different drugs and medications may interact with the medication within the ethinyl estradiol and norelgestromin patch. The ethinyl estradiol and norelgestromin patch will interact negatively with many cardiovascular medicines, or with medicines which can have side effects which act on the cardiovascular system. The ethinyl estradiol and norelgestromin patch is also likely to interact with other hormones.

Patients who are taking any of the following drugs should avoid using the ethinyl estradiol and norelgestromin patch. Interactions between the following drugs and the ethinyl estradiol and norelgestromin patch may be numerous and serious. Patients taking any of the following drugs who wish to begin using the ethinyl estradiol and norelgestromin patch should consult with their doctor to discover alternative treatments.

  • Amprenavir
  • Bexarotene
  • Boceprevir
  • Bosentan
  • Brigatinib
  • Carbamazepine
  • Carfilzomib
  • Dabrafenib
  • Dantrolene
  • Eslicarbazepine
  • Felbamate
  • Fosamprenavir
  • Fosphenytoin
  • Griseofulvin
  • Hemin
  • Lenalidomide
  • Mycophenolate mofetil
  • Mycophenolic acid
  • Oxcarbazepine
  • Phenobarbital
  • Phenytoin
  • Pomalidomide
  • Primidone
  • Rifabutin
  • Rifampin
  • Rifapentine
  • St. john's wort
  • Sugammadex
  • Telaprevir
  • Thalidomide
  • Tizanidine
  • Tranexamic acid

Interactions may include decreased blood levels of ethinyl estradiol and norelgestromin (a catastrophic failure in hormonal contraceptives, as it may render the treatment completely ineffective), increased risk of stroke, increased risk of heart attack, and decreases in the effectiveness of the other drug(s).

Ethinyl estradiol and norelgestromin may react negatively with some cancer drugs, such as carfilzomib (used to treat Kahler's disease). By using the ethinyl estradiol and norelgestromin patch while taking cancer drugs like carfilzomib, patients will put themselves at significant risk of dangerous blood clots. Risk of this is compounded by age, smoking habits, and other factors. Patients who are taking a cancer drug such as carfilzomib should not use the ethinyl estradiol and norelgestromin patch, and instead explore alternative options for birth control.

Ethinyl estradiol and norelgestromin may interact negatively with anticonvulsants and seizure medications, such as oxcarbazepine. Such anticonvulsants may lower the blood levels of ethinyl estradiol and norelgestromin to such a degree that the ethinyl estradiol and norelgestromin patch becomes essentially useless as a form of birth control. Patients who are taking an anticonvulsant such as oxcarbazepine should not use the ethinyl estradiol and norelgestromin patch, and instead consult with their doctor to discover alternative forms of birth control. Patients should make sure their doctor is completely aware of any and all drugs, supplements, and medications they are taking prior to deciding to us a ethinyl estradiol and norelgestromin patch.

The following drugs will interact with ethinyl estradiol and norelgestromin, but not necessarily with the same severity or with the same frequency as the drugs listed above. Patients who are taking any of the following drugs who would like to begin using the ethinyl estradiol and norelgestromin patch should consult with their doctor. Dosage adjustments or alternative treatments may be necessary.

  • Acarbose
  • Acetohexamide
  • Adalimumab
  • Albiglutide
  • Alefacept
  • Alogliptin
  • Amikacin
  • Aminoglutethimide
  • Aminophylline
  • Amobarbital
  • Amoxicillin
  • Ampicillin
  • Anakinra
  • Anastrozole
  • Anisindione
  • Aprepitant
  • Armodafinil
  • Atazanavir
  • Azithromycin
  • Aztreonam
  • Bacampicillin
  • Bacitracin
  • Betamethasone
  • Budesonide
  • Butabarbital
  • Butalbital
  • C1 esterase inhibitor
  • Canagliflozin
  • Canakinumab
  • Carbenicillin
  • Cefaclor
  • Cefadroxil
  • Cefamandole
  • Cefazolin
  • Cefdinir
  • Cefditoren
  • Cefepime
  • Cefixime
  • Cefmetazole
  • Cefonicid
  • Cefoperazone
  • Cefotaxime
  • Cefotetan
  • Cefoxitin
  • Cefpodoxime
  • Cefprozil
  • Ceftaroline
  • Ceftazidime
  • Ceftibuten
  • Ceftizoxime
  • Ceftriaxone
  • Cefuroxime
  • Cephalexin
  • Cephalothin
  • Cephapirin
  • Cephradine
  • Certolizumab
  • Chenodeoxycholic acid
  • Chloramphenicol
  • Chlorpromazine
  • Chlorpropamide
  • Cinoxacin
  • Ciprofloxacin
  • Clarithromycin
  • Clindamycin
  • Clobazam
  • Clotrimazole
  • Cloxacillin
  • Clozapine
  • Cobicistat
  • Colesevelam
  • Colistimethate
  • Conestat alfa
  • Conivaptan
  • Corticorelin
  • Corticotropin
  • Cortisone
  • Cosyntropin
  • Cyclosporine
  • Dalbavancin
  • Dapagliflozin
  • Daptomycin
  • Darunavir
  • Dasatinib
  • Deferasirox
  • Deflazacort
  • Delafloxacin
  • Demeclocycline
  • Dexamethasone
  • Dicloxacillin
  • Dicumarol
  • Diltiazem
  • Dirithromycin
  • Divalproex sodium
  • Doripenem
  • Doxycycline
  • Dronedarone
  • Dulaglutide
  • Efavirenz
  • Eliglustat
  • Elvitegravir
  • Empagliflozin
  • Enasidenib
  • Enoxacin
  • Enzalutamide
  • Ertapenem
  • Erythromycin
  • Etanercept
  • Exemestane
  • Exenatide
  • Flibanserin
  • Fluconazole
  • Fludrocortisone
  • Fluvoxamine
  • Fosaprepitant
  • Furazolidone
  • Gatifloxacin
  • Gemifloxacin
  • Gentamicin
  • Glimepiride
  • Glipizide
  • Glyburide
  • Golimumab
  • Grepafloxacin
  • Guselkumab
  • Hydrocortisone
  • Imatinib
  • Infliximab
  • Insulin
  • Insulin aspart
  • Insulin aspart protamine
  • Insulin degludec
  • Insulin detemir
  • Insulin glargine
  • Insulin glulisine
  • Insulin inhalation (rapid acting)
  • Insulin isophane
  • Insulin lispro
  • Insulin lispro protamine
  • Insulin regular
  • Insulin zinc
  • Insulin zinc extended
  • Isavuconazonium
  • Itraconazole
  • Ivacaftor
  • Ixekizumab
  • Kanamycin
  • Ketoconazole
  • Lamotrigine
  • Lapatinib
  • Lesinurad
  • Letermovir
  • Letrozole
  • Levofloxacin
  • Levothyroxine
  • Linaclotide
  • Linagliptin
  • Lincomycin
  • Linezolid
  • Liothyronine
  • Liotrix
  • Liraglutide
  • Lixisenatide
  • Lomefloxacin
  • Lomitapide
  • Loracarbef
  • Mephobarbital
  • Meropenem
  • Metformin
  • Methicillin
  • Methylprednisolone
  • Metreleptin
  • Metronidazole
  • Metyrapone
  • Mezlocillin
  • Mibefradil
  • Miconazole
  • Mifepristone
  • Miglitol
  • Miltefosine
  • Minocycline
  • Mirtazapine
  • Mitotane
  • Modafinil
  • Moxifloxacin
  • Nafcillin
  • Nalidixic acid
  • Nateglinide
  • Nefazodone
  • Nelfinavir
  • Neomycin
  • Netilmicin
  • Nevirapine
  • Nilotinib
  • Nitrofurantoin
  • Norfloxacin
  • Novobiocin
  • Ofloxacin
  • Olaparib
  • Oritavancin
  • Ospemifene
  • Oxacillin
  • Oxtriphylline
  • Oxytetracycline
  • Paromomycin
  • Penicillin g benzathine
  • Penicillin g potassium
  • Penicillin g sodium
  • Penicillin v potassium
  • Pentobarbital
  • Perampanel
  • Phenylbutazone
  • Piperacillin
  • Pirfenidone
  • Polymyxin b
  • Posaconazole
  • Pramlintide
  • Prednisolone
  • Prednisone
  • Procaine penicillin
  • Raloxifene
  • Repaglinide
  • Rilonacept
  • Ritonavir
  • Roflumilast
  • Romidepsin
  • Ropinirole
  • Rosiglitazone
  • Rufinamide
  • Saquinavir
  • Sarilumab
  • Saxagliptin
  • Secobarbital
  • Secukinumab
  • Selegiline
  • Siltuximab
  • Sirolimus
  • Sitagliptin
  • Sparfloxacin
  • Streptomycin
  • Sulfadiazine
  • Sulfadoxine
  • Sulfamethizole
  • Sulfamethoxazole
  • Sulfasalazine
  • Sulfinpyrazone
  • Sulfisoxazole
  • Tacrolimus
  • Tedizolid
  • Telithromycin
  • Telotristat
  • Teriflunomide
  • Testolactone
  • Tetracycline
  • Theophylline
  • Thyroid desiccated
  • Ticarcillin
  • Tigecycline
  • Tinidazole
  • Tipranavir
  • Tobramycin
  • Tocilizumab
  • Tolazamide
  • Tolbutamide
  • Topiramate
  • Triamcinolone
  • Triamcinolone ophthalmic
  • Troglitazone
  • Troleandomycin
  • Trovafloxacin
  • Ulipristal
  • Ustekinumab
  • Valdecoxib
  • Valproic acid
  • Vancomycin
  • Vandetanib
  • Vemurafenib
  • Voriconazole
  • Warfarin
  • Acebutolol
  • Acetaminophen
  • Amoxapine
  • Ascorbic acid
  • Atorvastatin
  • Brivaracetam
  • Carvedilol
  • Chlordiazepoxide
  • Cimetidine
  • Clomipramine
  • Clonazepam
  • Clorazepate
  • Delavirdine
  • Desipramine
  • Diazepam
  • Diflunisal
  • Doxepin
  • Estazolam
  • Ethanol
  • Etravirine
  • Flurazepam
  • Frovatriptan
  • Halazepam
  • Hyaluronidase
  • Imipramine
  • Indinavir
  • Labetalol
  • Lorazepam
  • Melatonin
  • Metoprolol
  • Midazolam
  • Naratriptan
  • Nortriptyline
  • Oxazepam
  • Penbutolol
  • Pioglitazone
  • Propranolol
  • Protriptyline
  • Quazepam
  • Rosuvastatin
  • Saw palmetto
  • Tegaserod
  • Temazepam
  • Ticagrelor
  • Timolol
  • Triazolam
  • Trimipramine
  • Zidovudine
  • Zolmitriptan
  • The ethinyl estradiol and norelgestromin will interact negatively with many fluoroquinolone antibiotics, such as ciprofloxacin. Fluoroquinolone antibiotics may diminish the effects of the ethinyl estradiol and norelgestromin patch, rendering it less effective than other forms of birth control and possibly leading to unplanned pregnancies. Patients who must begin taking fluoroquinolone antibiotics while using the ethinyl estradiol and norelgestromin patch should find an alternative form of birth control. Patients should make sure their doctor is aware of all drugs, supplements, and medications they are taking prior to deciding to use the ethinyl estradiol and norelgestromin patch.

The ethinyl estradiol in the ethinyl estradiol and norelgestromin patch may react negatively with alcohol and some foods. Patients who wish to begin using the ethinyl estradiol and norelgestromin patch should consult with their doctor to discover any dietary restrictions which may come with using the ethinyl estradiol and norelgestromin patch.

This is not necessarily a complete list of interactions between ethinyl estradiol and norelgestromin and other drugs. Patients should rely on their doctor to identify any potential interactions between any drugs they are currently taking and ethinyl estradiol and norelgestromin. In order to enable their doctor to do this, patients should disclose a complete list of any and all drugs, medications, and supplements to their doctor prior to deciding to use the ethinyl estradiol and norelgestromin patch.

Warnings

Patients who use the ethinyl estradiol and norelgestromin patch are at risk of venous thromboembolism (where a blood clot forms and then breaks loose, traveling around the patient's blood). Even among contraceptives, the ethinyl estradiol and norelgestromin patch puts the patients at serious relative risk of venous thromboembolism. Patients with preexisting conditions concerning the formation of blood clots may want to seek alternative treatments.

Patients with hypertension (high blood pressure) should not use the ethinyl estradiol and norelgestromin patch. By using the ethinyl estradiol and norelgestromin patch, patients with hypertension put themselves at a significantly increased risk of myocardial infarction (heart attack) and stroke. The use of the ethinyl estradiol and norelgestromin may also further increase the patient's blood pressure, which may present new health problems and further compound the risk of myocardial infarction and stroke. Patients with hypertension should consult with their doctor to discover alternative forms of contraception to the ethinyl estradiol and norelgestromin patch.

Patients who suffer from abnormal vaginal bleeding should not use the ethinyl estradiol and norelgestromin patch. Not only will the use of the ethinyl estradiol and norelgestromin patch likely exacerbate the patient's condition, it will also put the patient at increased risk of endometrial cancer.

Patients with estrogen-dependent cancers, such as breast cancer or endometrial (womb) cancer should not use the ethinyl estradiol and norelgestromin patch. By using the ethinyl estradiol and norelgestromin patch, patients will increase the rate of proliferation for the cancerous tumors. Patients with estrogen-dependent cancers should seek out alternative forms of birth control.

Patients with breast cancer induced hypercalcemia should not use the ethinyl estradiol and norelgestromin patch, as it will exacerbate their hypercalcemia. Hypercalcemia will weaken the patient's bones, force the creation of kidney stones, and eventually interfere with the functions of the heart and lung. Patients with breast cancer induced hypercalcemia should seek out an alternative form of birth control to the ethinyl estradiol and norelgestromin patch.

Patients with hepatic neoplasms (tumors in their liver) should not use the ethinyl estradiol and norelgestromin patch. Estrogens, such as ethinyl estradiol and norelgestromin, have been reported to cause both benign and cancerous tumor growth in the liver. As such, patients who already have tumor growth in their liver should avoid taking ethinyl estradiol and norelgestromin in order to avoid additional tumor growth. Patients with hepatic neoplasms should consult with their doctor to discover potential alternatives to the ethinyl estradiol and norelgestromin patch.

Patients with angioedema should exercise extreme caution when considering using the ethinyl estradiol and norelgestromin patch. The patch may exacerbate the patient's angioedema. Patients with angioedema may want to explore alternative forms of contraception to the ethinyl estradiol and norelgestromin patch. Patients with angioedema who insist on using the ethinyl estradiol and norelgestromin patch will require additional medical monitoring to ensure their safety.

Use of exogenous estrogens (which ethinyl estradiol and norelgestromin are) has been tied to a 2 to 4 fold increase in risk of gallbladder disease. For patients who already have gallbladder disease, the ethinyl estradiol and norelgestromin may exacerbate symptoms or bring about a resurgence of the disease. Patients with gallbladder disease or who are predisposed to gallbladder disease may want to explore alternative forms of contraception to the ethinyl estradiol and norelgestromin patch.

Patients with hypercalcemia should exercise caution when considering using the ethinyl estradiol and norelgestromin patch. The ethinyl estradiol and norelgestromin will increase intestinal absorption of calcium, which may exacerbate the patient's condition. Renal impairment may compound the risk of hypercalcemia. Patients with hypercalcemia should consult with their doctor to discover alternative, non-hormonal forms of birth control.

Ethinyl estradiol and norelgestromin are metabolized in the liver. Patients with hepatic impairment may not be able to metabolize the ethinyl estradiol and norelgestromin as effectively, leading to a higher steady state of the drugs in the patient's bloodstream and putting the patient at increased risk of negative side effects or even overdose. Patients with hepatic impairment or liver damage may want to seek out alternative forms of contraception to the ethinyl estradiol and norelgestromin patch. Patients with hepatic impairment who insist on using the ethinyl estradiol and norelgestromin patch will require additional medical monitoring in order to maintain the patient's safety.

The use of hormonal contraception (such as the ethinyl estradiol and norelgestromin patch) has been linked with depression. Patients with preexisting depression or other mental conditions should exercise caution when considering using the ethinyl estradiol and norelgestromin patch. Patients with depression may want to consider alternative forms of contraception to the ethinyl estradiol and norelgestromin patch. Patients who are using the ethinyl estradiol and norelgestromin patch should be aware that any feelings of sadness or depression may be the result of their ethinyl estradiol and norelgestromin patch, and not genuine feelings.

Ethinyl estradiol and norelgestromin can cause fluid retention. Patients with existing fluid retention problems should be aware that their use of the ethinyl estradiol and norelgestromin patch may exacerbate their condition. Excessive fluid retention may exacerbate some conditions such as asthma, epilepsy, and migraines.

Ethinyl estradiol and norelgestromin may cause glucose intolerance. Patients with diabetes should be aware that their use of the ethinyl estradiol and norelgestromin may complicate their condition, along with potentially throwing off medical tests.

The ethinyl estradiol and norelgestromin patch may cause retinal thrombosis. Patients should remain vigilant for signs of retinal thrombosis. Patients who develop retinal thrombosis may need to discontinue their use of the ethinyl estradiol and norelgestromin patch.

The ethinyl estradiol and norelgestromin patch may alter the results of a thyroid function test. Patients who need to undergo a thyroid function test while using the ethinyl estradiol and norelgestromin patch should consult with their doctor for directions on how to proceed.

Patients with high cholesterol should exercise caution when considering using the ethinyl estradiol and norelgestromin patch. Estrogen (which ethinyl estradiol and norelgestromin are) has been tied to increased cholesterol levels, which can, in turn, cause pancreatitis. Patients with high cholesterol may want to seek out alternative forms of contraception. If a patient with high cholesterol insists on using the ethinyl estradiol and norelgestromin patch, they will require additional medical monitoring to ensure that they stay healthy.

Patients who are pregnant should not use the ethinyl estradiol and norelgestromin patch. Human studies have found that ethinyl estradiol and norelgestromin can cause fetal abnormalities. On top of this, it is rare for women to become pregnant again while pregnant, making the risks far outweigh the positives for using the ethinyl estradiol and norelgestromin patch while pregnant. Additionally, patients who are breastfeeding should not use the ethinyl estradiol and norelgestromin patch. Ethinyl estradiol and norelgestromin can harm breastfeeding infants, as well as affect the volume of breast milk being produced.

This is not necessarily a comprehensive list of the risks associated with the use of ethinyl estradiol and norelgestromin. Patients should rely on their doctor to inform them of all of the risks that using the ethinyl estradiol and norelgestromin patch comes with. Patients should not use the ethinyl estradiol and norelgestromin patch unless they fully understand the risks of using it.

Storage

Skin patches should be kept at room temperature away from moisture and heat. Patients should never refrigerate or freeze the ethinyl estradiol and norelgestromin patches.

Patients should leave each ethinyl estradiol and norelgestromin patch in its foil pouch until they are ready to apply it.

Summary

The ethinyl estradiol and norelgestromin patch is a powerful hormonal contraceptive. As a powerful hormone, though, it can have a range of other, negative effects on both the patient's body and mind. Patients who hope to use the ethinyl estradiol and norelgestromin patch will have to make sure they don't have a range of medical conditions which contraindicate the patch's use, make sure they are taking none of the medications which interact with the patch, and be prepared to face the host of side effects that come with it. That is not to say that the ethinyl estradiol and norelgestromin is not safe, or effective though. Patients who give the ethinyl estradiol and norelgestromin patch the respect it demands, it can be used safely and effectively. The most common side effects are relatively mild, and none of the side effects can be as damaging as an unplanned pregnancy could be.